GlassScriptPhysician profile
Steven V Caridi
NPI 1124094800
$10,564.00
in general payments reported to CMS, 2019-2025
47 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $1,365 · 2021: $1,427 · 2022: $1,256 · 2023: $1,743 · 2024: $1,572 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,942.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,172.69 | 2019-2025 | Botox, Synthroid, Ubrelvy |
| Novo Nordisk INC | $1,387.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $878.41 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $791.38 | 2020-2025 | |
| Lilly USA, LLC | $743.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $589.47 | 2019-2022 | |
| Amarin Pharma, INC. | $491.43 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $362.47 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.06 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.95 | 2019-2022 | |
| Glaxosmithkline, LLC. | $196.44 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $177.33 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Cleerly, INC. | $170.90 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Exact Sciences Corporation | $161.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Heartflow, INC. | $144.76 | 2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $144.75 | 2019-2021 | |
| Sanofi Pasteur INC. | $129.29 | 2019-2023 | |
| Therapeuticsmd, INC. | $123.56 | 2020 | |
| Stryker Corporation | $121.02 | 2025 | Blueprint Patient Specific Instrumentation |
| Vivus LLC | $119.61 | 2019-2025 | Pancreaze |
| Seqirus USA INC | $119.08 | 2019-2024 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Galderma Laboratories, L.P. | $104.28 | 2019-2020 | |
| Amgen INC. | $99.02 | 2023-2024 | Repatha, Otezla, Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $98.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.45 | 2022-2023 | |
| Eisai INC. | $90.04 | 2020-2021 | |
| Axsome Therapeutics, INC. | $67.32 | 2025 | Symbravo |
| Idorsia Pharmaceuticals US INC | $62.58 | 2022-2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $41.67 | 2021 | |
| Astellas Pharma US INC | $31.64 | 2025 | Veozah |
| Arbor Pharmaceuticals, INC. | $30.13 | 2019 | |
| Medicure Pharma INC. | $28.38 | 2025 | Zypitamag |
| Photonicare INC | $27.20 | 2025 | Otosight Middle Ear Scope |
| Janssen Pharmaceuticals, INC | $26.41 | 2022 | |
| Valneva USA, INC. | $26.40 | 2025 | Ixchiq |
| Novartis Pharmaceuticals Corporation | $24.99 | 2024 | |
| Shield Therapeutics INC | $23.54 | 2024 | |
| Esperion Therapeutics, INC. | $22.68 | 2024 | Nexletol |
| Dermira, INC. | $22.58 | 2020 | |
| Ibsa Pharma INC. | $22.58 | 2022 | |
| Inspire Medical Systems, INC. | $22.31 | 2025 | Inspire |
| Lundbeck LLC | $19.32 | 2023 | Vyepti |
| Ethicon US, LLC | $19.18 | 2022 | |
| Medtronic Vascular, INC. | $18.09 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $17.10 | 2023 | Prehevbrio |
| Lucid Diagnostics INC. | $14.23 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Caridi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.